A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
allow for the importation of affordable and safe drugs 
by wholesale distributors, pharmacies, and individuals. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable and Safe 
4
Prescription Drug Importation Act’’. 
5
22:31 Jan 24, 2019
H447
2 
•HR 447 IH
SEC. 2. IMPORTING AFFORDABLE AND SAFE DRUGS. 
1
(a) IN GENERAL.—Section 804 of the Federal Food, 
2
Drug, and Cosmetic Act (21 U.S.C. 384) is amended to 
3
read as follows: 
4
‘‘SEC. 804. IMPORTATION OF SAFE AND AFFORDABLE 
5
DRUGS 
BY 
WHOLESALE 
DISTRIBUTORS, 
6
PHARMACIES, AND INDIVIDUALS. 
7
‘‘(a) IN GENERAL.—Not later than 180 days after 
8
the date of enactment of this section, the Secretary shall 
9
promulgate regulations permitting the importation of 
10
qualifying prescription drugs into the United States, in ac-
11
cordance with this section. 
12
‘‘(b) DEFINITIONS.—For purposes of this section: 
13
‘‘(1) CERTIFIED FOREIGN SELLER.—The term 
14
‘certified foreign seller’ means a licensed foreign 
15
pharmacy or foreign wholesale distributor that the 
16
Secretary certifies under subsection (d)(1)(B), that 
17
pays the fee required under subsection (d)(1)(C), 
18
and that is included on the list described in sub-
19
section (c). 
20
‘‘(2) FOREIGN
WHOLESALE
DISTRIBUTOR.— 
21
The term ‘foreign wholesale distributor’ means a 
22
person (other than a manufacturer, a manufactur-
23
er’s co-licensed partner, a third-party logistics pro-
24
vider, or a repackager) engaged in wholesale dis-
25
tribution. 
26
22:31 Jan 24, 2019
H447
3 
•HR 447 IH
‘‘(3) IMPORTER.—The term ‘importer’ means a 
1
dispenser (as defined in section 581(3)) or wholesale 
2
distributor registered under section 503(e) who im-
3
ports prescription drugs into the United States in 
4
accordance with this section. 
5
‘‘(4) LICENSED
FOREIGN
PHARMACY.—The 
6
term ‘licensed foreign pharmacy’ means a pharmacy 
7
located in Canada, or subject to subsection (e), an-
8
other applicable country, that— 
9
‘‘(A) operates in accordance with applica-
10
ble pharmacy standards set forth by the provin-
11
cial pharmacy rules and regulations enacted in 
12
Canada, or, subject to subsection (e), such ap-
13
plicable rules and regulations of the permitted 
14
country in which such seller is located; and 
15
‘‘(B) is licensed to operate and dispense 
16
prescription drugs to individuals in Canada, or, 
17
subject to subsection (e), the permitted country 
18
in which the pharmacy is located. 
19
‘‘(5) QUALIFYING
PRESCRIPTION
DRUG.—The 
20
term ‘qualifying prescription drug’— 
21
‘‘(A) means a prescription drug that— 
22
‘‘(i) is approved for use in patients, 
23
and marketed, in Canada, or subject to 
24
subsection (e), approved for use in pa-
25
22:31 Jan 24, 2019
H447
4 
•HR 447 IH
tients, and marketed, in another permitted 
1
country; 
2
‘‘(ii) is manufactured in a facility reg-
3
istered under subsection (b)(1) or (i) of 
4
section 510 that is in compliance with good 
5
manufacturing practices regulations of the 
6
Food and Drug Administration; 
7
‘‘(iii) has the same active ingredient 
8
or ingredients, route of administration, and 
9
strength as a prescription drug approved 
10
under chapter V, or, for purposes of sub-
11
paragraph (B)(iv), is biosimilar to an ap-
12
proved biological product and has the same 
13
route of administration and strength as the 
14
approved biological product; and 
15
‘‘(iv) is labeled in accordance with— 
16
‘‘(I) the laws of Canada, or an-
17
other country from which importation 
18
is permitted pursuant to subsection 
19
(e); and 
20
‘‘(II) the requirements promul-
21
gated by the Secretary, which shall in-
22
clude labeling in English; 
23
‘‘(B) with respect to importers only, in-
24
cludes— 
25
22:31 Jan 24, 2019
H447
5 
•HR 447 IH
‘‘(i) peritoneal dialysis solution; 
1
‘‘(ii) insulin; 
2
‘‘(iii) a drug for which a risk evalua-
3
tion and mitigation strategy is required 
4
under section 505–1; 
5
‘‘(iv) biological products, as defined in 
6
section 351 of the Public Health Service 
7
Act that are proteins (except any chemi-
8
cally synthesized polypeptides) or analo-
9
gous products; and 
10
‘‘(v) intravenously infused drugs; and 
11
‘‘(C) does not include— 
12
‘‘(i) a controlled substance (as defined 
13
in section 102 of the Controlled Sub-
14
stances Act); 
15
‘‘(ii) an anesthetic drug inhaled dur-
16
ing surgery; or 
17
‘‘(iii) a compounded drug. 
18
‘‘(6) VALID
PRESCRIPTION.—The term ‘valid 
19
prescription’ means a prescription that is issued for 
20
a legitimate medical purpose in the usual course of 
21
professional practice by— 
22
‘‘(A) a practitioner who has conducted at 
23
least 1 in-person medical evaluation of the pa-
24
tient; or 
25
22:31 Jan 24, 2019
H447
6 
•HR 447 IH
‘‘(B) a covering practitioner. 
1
‘‘(c) PUBLICATION OF CERTIFIED FOREIGN SELL-
2
ERS.—The Secretary shall publish on a dedicated internet 
3
website a list of certified foreign sellers, including the 
4
internet website address, physical address, and telephone 
5
number of each such certified foreign seller. 
6
‘‘(d) ADDITIONAL CRITERIA.— 
7
‘‘(1) CERTIFIED FOREIGN SELLERS.— 
8
‘‘(A) IN GENERAL.—To be a certified for-
9
eign seller, such seller shall— 
10
‘‘(i) be certified by the Secretary in 
11
accordance with subparagraph (B); 
12
‘‘(ii) pay the registration fee estab-
13
lished under subparagraph (C); and 
14
‘‘(iii) sell only qualifying prescription 
15
drugs to importers or individuals who im-
16
port prescription drugs into the United 
17
States in accordance with this section. 
18
‘‘(B) CERTIFICATION.—To be a certified 
19
foreign seller, the Secretary shall certify that 
20
such seller— 
21
‘‘(i) is a foreign wholesale distributor 
22
or licensed foreign pharmacy operating an 
23
establishment, which may include an online 
24
foreign pharmacy, that is located in Can-
25
22:31 Jan 24, 2019
H447
7 
•HR 447 IH
ada, or, subject to subsection (e), another 
1
permitted country; 
2
‘‘(ii) is engaged in the distribution or 
3
dispensing of a prescription drug that is 
4
imported or offered for importation into 
5
the United States; 
6
‘‘(iii) has been in existence for a pe-
7
riod of at least 5 years preceding the date 
8
of such certification and has a purpose 
9
other than to participate in the program 
10
established under this section; 
11
‘‘(iv) in the case of a certified foreign 
12
seller that is a licensed foreign pharmacy, 
13
agrees to dispense a qualifying prescription 
14
drug to an individual in the United States 
15
only after receiving a valid prescription, as 
16
described in paragraph (2)(C); 
17
‘‘(v) has processes established by the 
18
seller, or participates in another estab-
19
lished process, to certify that the physical 
20
premises and data reporting procedures 
21
and licenses are in compliance with all ap-
22
plicable laws and regulations of Canada, 
23
or, subject to subsection (e), the permitted 
24
country in which the seller is located, and 
25
22:31 Jan 24, 2019
H447
8 
•HR 447 IH
has implemented policies designed to mon-
1
itor ongoing compliance with such laws 
2
and regulations; 
3
‘‘(vi) conducts or commits to partici-
4
pate in ongoing and comprehensive quality 
5
assurance programs and implements such 
6
quality 
assurance 
measures, 
including 
7
blind testing, to ensure the veracity and re-
8
liability of the findings of the quality as-
9
surance program; 
10
‘‘(vii) agrees that, pursuant to sub-
11
section (g), laboratories approved by the 
12
Secretary may be authorized to conduct 
13
product testing to determine the chemical 
14
authenticity 
of 
sample 
pharmaceutical 
15
products; 
16
‘‘(viii) agrees to notify the Secretary, 
17
importers, and individuals of product re-
18
calls in Canada, or pursuant to subsection 
19
(e), the permitted country in which the 
20
seller is located, and agrees to cease, or re-
21
frain from, exporting such product; 
22
‘‘(ix) has established, or will establish 
23
or participate in, a process for resolving 
24
grievances, as defined by the Secretary, 
25
22:31 Jan 24, 2019
H447
9 
•HR 447 IH
and will be held accountable for violations 
1
of established guidelines and rules; 
2
‘‘(x) except as otherwise permitted 
3
under this section, does not sell products 
4
that the seller could not otherwise legally 
5
sell in Canada, or, subject to subsection 
6
(e), the permitted country in which such 
7
seller is located to customers in the United 
8
States; and 
9
‘‘(xi) meets any other criteria estab-
10
lished by the Secretary. 
11
‘‘(C) CERTIFICATION FEE.—Not later than 
12
30 days before the start of each fiscal year, the 
13
Secretary shall establish a fee to be collected 
14
from foreign sellers for such fiscal year that are 
15
certified under subparagraph (B), in an amount 
16
that is sufficient, and not more than necessary, 
17
to pay the costs of administering the program 
18
under this section, and enforcing this section 
19
pursuant to section 303(h), for that fiscal year. 
20
‘‘(D) RECERTIFICATION.—A certification 
21
under subparagraph (B) shall be in effect for a 
22
period of 2 years, or until there is a material 
23
change in the circumstances under which the 
24
foreign seller meets the requirements under 
25
22:31 Jan 24, 2019
H447
10 
•HR 447 IH
such subparagraph, whichever occurs earlier. A 
1
foreign seller may reapply for certification 
2
under such subparagraph (B), in accordance 
3
with a process established by the Secretary. 
4
‘‘(2) INDIVIDUALS.—An individual may import 
5
a qualifying prescription drug described in sub-
6
section (b) from Canada or another country pursu-
7
ant to subsection (e) if such drug— 
8
‘‘(A) is dispensed, including through an 
9
online pharmacy, by a certified foreign seller 
10
that is a licensed foreign pharmacy; 
11
‘‘(B) is purchased for personal use by the 
12
individual, not for resale, in quantities that do 
13
not exceed a 90-day supply; and 
14
‘‘(C) is filled only after providing to the li-
15
censed foreign pharmacy a valid prescription 
16
issued by a health care practitioner licensed to 
17
practice in a State in the United States. 
18
‘‘(e) IMPORTATION FROM OTHER COUNTRIES.—Be-
19
ginning on the date that is 2 years after the date on which 
20
final regulations are promulgated to carry out this section, 
21
if, based on a review of the evidence obtained after such 
22
effective date, including the reports submitted under sec-
23
tion 2(d) of the Affordable and Safe Prescription Drug 
24
Importation Act, that importation of qualifying prescrip-
25
22:31 Jan 24, 2019
H447
11 
•HR 447 IH
tion drugs from Canada under this section resulted in cost 
1
savings for consumers in the United States and increased 
2
access to safe medication, the Secretary shall have the au-
3
thority to permit importation of qualifying prescription 
4
drugs by importers and individuals from, in addition to 
5
Canada, any country that— 
6
‘‘(1) is a member of the Organisation for Eco-
7
nomic Co-operation and Development; and 
8
‘‘(2) has statutory or regulatory standards for 
9
the approval and sale of prescription drugs that are 
10
comparable to the standards in the United States 
11
and that— 
12
‘‘(A) authorizes the approval of drugs only 
13
if a drug has been determined to be safe and 
14
effective by experts employed by or acting on 
15
behalf of a governmental entity and qualified by 
16
scientific training and experience to evaluate 
17
the safety and effectiveness of drugs; 
18
‘‘(B) requires that any determination of 
19
safety and effectiveness described in subpara-
20
graph (A) be made on the basis of adequate 
21
and well-controlled investigations, including 
22
clinical investigations, as appropriate, con-
23
ducted by experts qualified by scientific training 
24
22:31 Jan 24, 2019
H447
12 
•HR 447 IH
and experience to evaluate the safety and effec-
1
tiveness of drugs; 
2
‘‘(C) requires the methods used in, and the 
3
facilities and controls used for, the manufac-
4
ture, processing, and packing of drugs in the 
5
country to be adequate to preserve the identity, 
6
quality, purity, and strength of the drugs; and 
7
‘‘(D) requires the reporting of adverse re-
8
actions to drugs and establish procedures to re-
9
call, and withdraw approval of, drugs found not 
10
to be safe or effective. 
11
‘‘(f) LABELING.—Any qualifying prescription drug 
12
imported that meets the labeling requirements described 
13
in subsection (b)(5)(A)(iv) is deemed not misbranded for 
14
purposes of section 502. 
15
‘‘(g) DRUG
TESTING
LABORATORIES.—The Sec-
16
retary may approve one or more laboratories to conduct 
17
random testing of prescription drugs sold by certified for-
18
eign sellers to assess the chemical authenticity of such 
19
drugs. 
20
‘‘(h) UNFAIR AND DISCRIMINATORY ACTS AND PRAC-
21
TICES.—It is unlawful for a manufacturer, directly or indi-
22
rectly (including by being a party to a licensing agreement 
23
or other agreement)— 
24
22:31 Jan 24, 2019
H447
13 
•HR 447 IH
‘‘(1) to discriminate by charging a higher price 
1
for a prescription drug sold to a certified foreign 
2
seller that sells such drug to an importer in accord-
3
ance with this section than the price that is charged, 
4
inclusive of rebates or other incentives to the coun-
5
try from which the drug is exported, to another per-
6
son that is in the same country and that does not 
7
import such a drug into the United States in accord-
8
ance with this section; 
9
‘‘(2) except with respect to a prescription drug 
10
on the drug shortage list under section 506E, dis-
11
criminate by denying, restricting, or delaying sup-
12
plies of a prescription drug to a certified foreign sell-
13
er, on account of such seller’s status as a certified 
14
foreign seller, that sells such drug to an importer in 
15
accordance with this section, or by publicly, pri-
16
vately, or otherwise refusing to do business with 
17
such a certified foreign seller on account of such 
18
seller’s status as a certified foreign seller; 
19
‘‘(3) cause there to be a difference (including a 
20
difference in active ingredient, route of administra-
21
tion, bioequivalence, strength, formulation, manufac-
22
turing establishment, manufacturing process, or per-
23
son that manufactures the drug) between a prescrip-
24
tion drug for distribution in the United States and 
25
22:31 Jan 24, 2019
H447
14 
•HR 447 IH
the drug for distribution in Canada or another per-
1
mitted country, subject to subsection (e), for the 
2
purpose of avoiding sales by certified foreign sellers; 
3
or 
4
‘‘(4) except with respect to a prescription drug 
5
on the drug shortage list under section 506E, en-
6
gage in any other action to restrict, prohibit, or 
7
delay the importation of a prescription drug under 
8
this section. 
9
‘‘(i) INFORMATION AND RECORDS.— 
10
‘‘(1) BIANNUAL REPORTS.—Each importer shall 
11
submit biannual reports to the Secretary which shall 
12
contain, for each qualifying prescription drug im-
13
ported into the United States— 
14
‘‘(A) the unique facility identifier of the 
15
manufacturer of the drug, described in section 
16
510; 
17
‘‘(B) the transaction information described 
18
in section 581(26) (other than the information 
19
described in subparagraph (C)); and 
20
‘‘(C) the price paid by the importer for the 
21
drug. 
22
‘‘(2) MAINTENANCE
OF
RECORDS
BY
SEC-
23
RETARY.—The Secretary shall maintain information 
24
and documentation submitted under paragraph (1) 
25
22:31 Jan 24, 2019
H447
15 
•HR 447 IH
for such period of time as the Secretary determines 
1
to be appropriate. 
2
‘‘(j) SUSPENSION OF IMPORTATION.— 
3
‘‘(1) PATTERNS
OF
NONCOMPLIANCE.—The 
4
Secretary shall require that importation of a specific 
5
qualifying prescription drug or importation by a spe-
6
cific certified foreign seller or importer pursuant to 
7
this section be immediately suspended if the Sec-
8
retary determines that there is a pattern of importa-
9
tion of such specific drug or by such specific seller 
10
or importer that involves counterfeit drugs, drugs 
11
that have been recalled or withdrawn, or drugs in 
12
violation of any requirement of this section, until an 
13
investigation is completed and the Secretary deter-
14
mines that importation of such drug or by such sell-
15
er or importer does not endanger the public health. 
16
‘‘(2) TEMPORARY SUSPENSION.—The Secretary 
17
may require that importation of a specific qualifying 
18
prescription drug or importation by a specific cer-
19
tified foreign seller or importer pursuant to this sec-
20
tion be temporarily suspended if, with respect to 
21
such drug, seller, or importer, there is a violation of 
22
any requirement of this section or if the Secretary 
23
determines that importation of such drug or by such 
24
seller or importer might endanger the public health. 
25
22:31 Jan 24, 2019
H447
16 
•HR 447 IH
Such temporary suspension shall apply until the Sec-
1
retary completes an investigation and determines 
2
that importation of such drug or by such seller or 
3
importer does not endanger the public health. 
4
‘‘(k) SUPPLY CHAIN SECURITY.— 
5
‘‘(1) PURCHASE FROM REGISTERED FACILITIES 
6
AND CERTIFIED FOREIGN SELLERS.— 
7
‘‘(A) IN GENERAL.—Except as provided in 
8
subparagraph (B), certified foreign sellers who 
9
sell qualifying prescription drugs for importa-
10
tion into the United States pursuant to this 
11
section may purchase such drugs only from 
12
manufacturers or entities registered under sec-
13
tion 510 or other certified foreign sellers. 
14
‘‘(B) EXCEPTION.—Certified foreign sellers 
15
who sell qualifying prescription drugs for im-
16
portation into the United States pursuant to 
17
this section may purchase such drugs from for-
18
eign sellers in Canada or another permitted 
19
country, even if such foreign seller is not a 
20
manufacturer registered under section 510 or a 
21
certified foreign seller, if the Secretary enters 
22
into a memorandum of understanding or coop-
23
erative agreement with Canada, or such other 
24
permitted country, to ensure compliance, to the 
25
22:31 Jan 24, 2019
H447
17 
•HR 447 IH
extent appropriate and feasible, with subchapter 
1
H of chapter V. The Secretary shall seek to 
2
enter into such a memorandum of under-
3
standing or cooperative agreement with Canada 
4
and each country from which importation is 
5
permitted under subsection (e). 
6
‘‘(2) IMPORTATION TRACING.—Certified foreign 
7
sellers shall provide importers with the unique facil-
8
ity identifier associated with the manufacturer reg-
9
istered under section 510 of the qualifying prescrip-
10
tion drug and the information under paragraph 
11
(25), paragraph (26) (other than subparagraph (C)), 
12
and subparagraphs (D), (F), and (G) of paragraph 
13
(27) of section 581. Certified foreign sellers shall 
14
provide such information to individuals purchasing 
15
such drugs, upon request. 
16
‘‘(l) REMS.—In the case of an importer that imports 
17
a qualifying prescription drug, where the drug with the 
18
same active ingredient or ingredients (or that is biosimilar 
19
to an approved biological product), route of administra-
20
tion, and strength that is approved under chapter V or 
21
section 351 of the Public Health Service Act is subject 
22
to elements to assure safe use under section 505–1, such 
23
importer shall be subject to such elements to assure safe 
24
use, as applicable and appropriate. 
25
22:31 Jan 24, 2019
H447
18 
•HR 447 IH
‘‘(m) CONSTRUCTION.—Nothing in this section limits 
1
the authority of the Secretary relating to the importation 
2
of prescription drugs, other than with respect to section 
3
801(d)(1) as provided in this section.’’. 
4
(b) PENALTIES WITH RESPECT TO ONLINE PHAR-
5
MACIES.—Section 303 of the Federal Food, Drug, and 
6
Cosmetic Act (21 U.S.C. 333) is amended by adding at 
7
the end the following: 
8
‘‘(h) In the case of person operating an internet 
9
website, whether in the United States or in another coun-
10
try, that violates section 301(aa) by— 
11
‘‘(1) selling, by means of the internet, with the 
12
intent to defraud or mislead or with reckless dis-
13
regard for safety of the public, an adulterated or 
14
counterfeit drug to an individual in the United 
15
States; or 
16
‘‘(2) dispenses, by means of the internet, a drug 
17
to an individual in the United States who the person 
18
knows or has reasonable cause to believe, does not 
19
possess a valid prescription for that drug, 
20
such person shall be imprisoned for not more than 
21
10 years or fined not more than $250,000.’’. 
22
(c) NO PREEMPTION.—Nothing in this Act, including 
23
the amendments made by this Act, shall be construed to 
24
preempt, alter, displace, abridge, or supplant any remedy 
25
22:31 Jan 24, 2019
H447
19 
•HR 447 IH
available under any State or Federal law, including com-
1
mon law, that provides a remedy for civil relief. 
2
(d) REPORTS.— 
3
(1) HHS.—Not later than 1 year after the date 
4
on which final regulations are promulgated to carry 
5
out section 804 of the Federal Food, Drug, and Cos-
6
metic Act (21 U.S.C. 384), as amended by this Act, 
7
and every 2 years thereafter, the Secretary of 
8
Health and Human Services, after consultation with 
9
appropriate Federal agencies, shall submit to Con-
10
gress and make public a report on the importation 
11
of drugs into the United States. 
12
(2) GAO REPORT.—Not later than 18 months 
13
after the date on which final regulations are promul-
14
gated to carry out section 804 of the Federal Food, 
15
Drug, and Cosmetic Act (21 U.S.C. 384), as amend-
16
ed by this Act, the Comptroller General of the 
17
United States shall submit to Congress a report con-
18
taining an analysis of the implementation of the 
19
amendments made by this Act, including a review of 
20
drug safety and cost-savings and expenses, including 
21
cost-savings to consumers in the United States and 
22
trans-shipment and importation tracing processes, 
23
resulting from such implementation. 
24
Æ 
22:31 Jan 24, 2019
H447
